Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(29 sites)

Japan

Ehime University Hospital, Ehime

Department of Neurology and Stroke Center, Southern Tohoku Clinic., Fukushima

Hiroshima University Hospital, Hiroshima

NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima

Asahikawa Medical University Hospital, Hokkaido

Itami City Hospital, Hyōgo

JA-Ibaraki Tsuchiura Kyodo General Hospital, Ibaraki

University of Tsukuba Hospital, Ibaraki

Kagoshima University Hospital, Kagoshima

Tanaka Neurosurgical Clinic, Kagoshima

St. Marianna University School of Medicine Hospital, Kanagawa

Yokohama City University Hospital, Kanagawa

Kumamoto Ezuko Rehabilitation Medical Center, Kumamoto

NHO Nagasaki Medical Center, Nagasaki

Koide Clinic of Epilepsy and Neurological Disorders, Osaka

Osaka University Hospital, Osaka

Shintokukai Nii Neurosurgery and Psychiatry Clinic, Osaka

Ochiai Brain Clinic, Saitama

TMG ASAKA Medical Center, Saitama

Sakurai Clinic, Shiga

NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka

Seirei Hamamatsu General Hospital, Shizuoka

Seirei Mikatahara General Hospital, Shizuoka

Jichi Medical University Hospital, Tochigi

Tokushima University Hospital, Tokushima

Medical Hospital, Tokyo Medical and Dental University, Tokyo

National Center of Neurology and Psychiatry, Tokyo

Tokyo Medical University Hospital, Tokyo

NHO Yamagata National Hospital, Yamagata